Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, ...
A groundbreaking new oral medication for weight management has shown promising results in a recent large-scale clinical trial, offering hope to millions with obesity and related health issues.
Orforglipron (LY3502970) is a small-molecule, non-peptide GLP-1RA designed for oral use. Compared to popular GLP-1RAs like semaglutide, orforglipron does not require injection or an absorption ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results